Gefitinib/osimertinib-resistant NSCLC cells and clinical samples with acquired resistance to EGFR-TKIs exhibit elevated expression of stem cell-related markers, including ALDH1A1, Sox2, Oct4, and Nanog, and acquire stem cell-like properties [10–12]. Here, EGFR is linked to non-small cell lung carcinoma.